Beschreibung
Osteosarcoma is a primary bone cancer that arises in developing bones in young adults who are experiencing growing spurts. Chemotherapy is the most common successful treatment used currently, but there are many limitations and side effects caused by these DNA damaging chemotherapies to osteosarcoma patients. The five-year survival rate for osteosarcoma is very poor in that 40% of the patients die due to their osteosarcomas and the remaining 60% who are cured of their osteosarcoma succumb to heart failure or secondary cancers. Chemotherapy regimens used to treat osteosarcoma patients result in anti-tumour activity by exerting DNA damage. This study investigated the efficacy and safety of a chosen panel of chemotherapy drugs on murine osteosarcoma (OS) cell lines.
Autorenporträt
Thanuri Jeevananda is a Microbiologist, a researcher who has received B.Sc. in Microbiology and M.Sc. in Biotechnology. Her educational background in science and technology has always mesmerised her to investigate towards new branches and she successfully completed her research on new treatments for Osteosarcoma at La Trobe University, Melbourne.
Herstellerkennzeichnung:
OmniScriptum SRL
Str. Armeneasca 28/1, office 1
2012 Chisinau
MD
E-Mail: info@omniscriptum.com
